brentuximab vedotin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
synthetic derivatives of dolastatin series	4964	914088-09-8

Description:

Molecule	Description
Synonyms: brentuximab vedotin adcetris SGN-35 cAC10-vcMMAE brentuximab vedotin (genetical recombination)	a CD30-directed antibody-drug conjugate consisting of three components: the chimeric IgG1 antibody cAC10, specific for human CD30, the microtubule disrupting agent MMAE, and a protease-cleavable linker that covalently attaches MMAE to cAC10 Molecular weight: Formula: Brentuximab(C68H106N11O15S)3-5 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

brentuximab vedotin
adcetris
SGN-35
cAC10-vcMMAE
brentuximab vedotin (genetical recombination)

a CD30-directed antibody-drug conjugate consisting of three components: the chimeric IgG1 antibody cAC10, specific for human CD30, the microtubule disrupting agent MMAE, and a protease-cleavable linker that covalently attaches MMAE to cAC10

Molecular weight:
Formula: Brentuximab(C68H106N11O15S)3-5
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Show entries

Search:

Date	Agency	Company
Aug. 19, 2011	FDA	SEATTLE GENETICS
Jan. 17, 2014	PMDA	Takeda Pharmaceutical Company Limited
Oct. 25, 2012	EMA	Takeda Pharma A/S

Showing 1 to 3 of 3 entries

Previous1Next

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	255.64	27.29	149	5593	118300	63364980
Neuropathy peripheral	234.73	27.29	139	5603	113528	63369752
Off label use	152.60	27.29	240	5502	674222	62809058
Neutropenia	150.20	27.29	125	5617	174880	63308400
Disease progression	99.60	27.29	85	5657	122673	63360607
Pneumocystis jirovecii pneumonia	95.49	27.29	41	5701	16873	63466407
Polyneuropathy	87.78	27.29	37	5705	14552	63468728
Thrombocytopenia	82.61	27.29	84	5658	151073	63332207
Pyrexia	71.33	27.29	141	5601	470337	63012943
Neutrophil count decreased	53.89	27.29	43	5699	56363	63426917

Showing 1 to 10 of 36 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuropathy peripheral	177.18	21.65	148	7749	83115	34865919
Off label use	173.71	21.65	325	7572	419199	34529835
Febrile neutropenia	145.09	21.65	166	7731	136683	34812351
Cytomegalovirus chorioretinitis	109.10	21.65	38	7859	3551	34945483
Disease progression	102.56	21.65	124	7773	107953	34841081
Polyneuropathy	96.63	21.65	53	7844	14843	34934191
Neutropenia	88.54	21.65	140	7757	156638	34792396
Pneumocystis jirovecii pneumonia	73.10	21.65	49	7848	19661	34929373
Pyrexia	68.83	21.65	197	7700	332816	34616218
Endocarditis noninfective	65.29	21.65	13	7884	127	34948907

Showing 1 to 10 of 47 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	328.24	20.98	276	11963	230723	79501426
Neuropathy peripheral	327.11	20.98	226	12013	141079	79591070
Off label use	238.15	20.98	464	11775	906751	78825398
Disease progression	214.75	20.98	197	12042	184165	79547984
Neutropenia	205.23	20.98	236	12003	287474	79444675
Pneumocystis jirovecii pneumonia	158.42	20.98	84	12155	32424	79699725
Polyneuropathy	127.91	20.98	66	12173	24085	79708064
Neutrophil count decreased	124.24	20.98	108	12131	93851	79638298
Thrombocytopenia	115.82	20.98	171	12068	265088	79467061
Pyrexia	115.66	20.98	293	11946	678416	79053733

Showing 1 to 10 of 82 entries

Previous1 2 3 4 5…9Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L01FX05	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES Other monoclonal antibodies and antibody drug conjugates
FDA CS	M0028142	Immunoconjugates
FDA EPC	N0000182967	CD30-directed Immunoconjugate
FDA MoA	N0000182966	CD30-directed Antibody Interactions
FDA PE	N0000175085	Microtubule Inhibition
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D000074322	Antineoplastic Agents, Immunological
MeSH PA	D018796	Immunoconjugates
MeSH PA	D007155	Immunologic Factors
MeSH PA	D000922	Immunotoxins

Showing 1 to 10 of 11 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID
CD30-positive peripheral T-cell lymphoma	indication	109977009
Hodgkin's disease	indication	118599009
Cutaneous Tcell lymphoma	indication	400122007
Anaplastic large T-cell systemic malignant lymphoma	indication	404134006

Showing 1 to 4 of 4 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Tumor necrosis factor receptor superfamily member 8	Membrane receptor	P28908	TNR8_HUMAN	BINDING AGENT				DRUG LABEL	DRUG LABEL
Tubulin beta	Tumour-associated antigen	P07437 Q9H4B7 Q13885 Q9BVA1 Q13509 P04350 P68371 Q9BUF5 Q3ZCM7	TBB5_HUMAN TBB1_HUMAN TBB2A_HUMAN TBB2B_HUMAN TBB3_HUMAN TBB4A_HUMAN TBB4B_HUMAN TBB6_HUMAN TBB8_HUMAN	INHIBITOR				DRUG LABEL	DRUG LABEL

Showing 1 to 2 of 2 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
013904	NDDF
1147320	RXNORM
117723179	PUBCHEM_CID
185268	MMSL
28063	MMSL
4031047	VUID
4031047	VANDF
6772	IUPHAR_LIGAND_ID
713395006	SNOMEDCT_US
714671006	SNOMEDCT_US

Showing 1 to 10 of 19 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ADCETRIS	HUMAN PRESCRIPTION DRUG LABEL	1	51144-050	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	BLA	27 sections
ADCETRIS	HUMAN PRESCRIPTION DRUG LABEL	1	51144-050	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	BLA	27 sections
ADCETRIS	HUMAN PRESCRIPTION DRUG LABEL	1	51144-050	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	BLA	27 sections
ADCETRIS	HUMAN PRESCRIPTION DRUG LABEL	1	51144-050	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	BLA	27 sections

Showing 1 to 4 of 4 entries

Previous1Next